Condition: Alagille Syndrome · Sponsor: Ipsen
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives. Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching. The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
This description comes directly from the study's public registry record.
Ipsen Recruitment Enquiries · See email · clinical.trials@ipsen.com
Always discuss trial participation with your own doctor first.
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| UCSF Benioff Children's Hospital | San Francisco, California, United States | Recruiting |
| The Children's Mercy Hospital | Kansas City, Missouri, United States | Recruiting |
| SSM Health Cardinal Glennon Children's Hospital | St Louis, Missouri, United States | Not Yet Recruiting |
| NYU Langone - NYU Grossman School of Medicine | New York, New York, United States | Recruiting |
| Columbia University Medical Center - Morgan Stanley Children's Hospital of NewYork - Presbyterian (MS-CHONY) | New York, New York, United States | Recruiting |
| Le Bonheur Children's Hospital | Memphis, Tennessee, United States | Recruiting |
| Children's Medical Center Of Dallas | Dallas, Texas, United States | Recruiting |
| Proactive El Paso,LLC | El Paso, Texas, United States | Recruiting |
| Primary Children's Hospital (PCH) - Intermountain Healthcare/University of Utah | Salt Lake City, Utah, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06850038